Press Releases | Organogenesis Holdings Inc.

Search

Year

Organogenesis Expands Manufacturing Capacity to Support Future Growth

CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced

November 22, 2024

PDF Version

Organogenesis Commends Final LCDs

CANTON, Mass., November 14, 2024 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, commends today’s decision

November 14, 2024

PDF Version

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported

November 12, 2024

PDF Version

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the

November 12, 2024

PDF Version

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today

November 11, 2024

PDF Version

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today

October 16, 2024

PDF Version

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis believes published study satisfies requirements for Medicare coverage under proposed Local Coverage Determination (LCDs) CANTON, Mass., Oct.

October 1, 2024

PDF Version

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today

September 4, 2024

PDF Version

Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results

CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported

August 8, 2024

PDF Version

Organogenesis Shares ReNu® Program Update

On track to submit ReNu BLA by the end of 2025 Enrollment in second Phase 3 complete; significantly ahead of expectations Subgroup analysis demonstrated most severe (KL4) subjects responded comparably to moderate (KL3) CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc.

August 8, 2024

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 19